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Introduction. The hyperdense internal carotid artery sign (HICAS) has been suggested as a common marker of terminal internal
carotid artery (ICA) thrombus associated with poor outcomes following thrombolysis. We aimed to investigate the prevalence
and prognostic signiﬁcance of the HICAS in an unselected cohort of patients receiving intravenous thrombolysis. Methods.
Prethrombolysis NCCTs of 120 patients were examined for the presence of the HICAS and hyperdense middle cerebral artery sign
(HMCAS). A poor outcome was deﬁned as a discharge Barthel score <15 or inpatient death. Results. A HICAS was present in 3
patients(2.5%).Prethrombolysisneurologicaldeﬁcitswere signiﬁcantlymoresevereinpatientswithaHICAS(P = 0.019).HICAS
wasnotsigniﬁcantlyassociatedwithapooroutcome(P = 0.323).HMCASwassigniﬁcantlyassociatedwithsevereprethrombolysis
neurological deﬁcits (P = 0.0025) and a poor outcome (P = 0.015). Conclusions. This study suggests that the prevalence of the
HICAS may be lower than previously reported. The presence of a HICAS was associated with severe prethrombolysis neurological
deﬁcits in keeping with terminal ICA occlusion. The role of the HICAS as a prognostic marker in stroke thrombolysis remains
unclear.
1.Introduction
Despite advances in magnetic resonance imaging, noncon-
trastcomputedtomography (NCCT)remains themostcom-
monly used imaging modality in acute stroke. Early ischemic
changes on NCCT, particularly those in the territory of the
middle cerebral artery (MCA),have diagnostic and prognos-
tic implications in patients receiving thrombolytic therapy
[1, 2]. However, these changes are often subtle and as such
may be of variable reliability [3–6].
The hyperdense middle cerebral artery sign (HMCAS)
is a well-established marker of intraluminal MCA thrombus
and was amongst the ﬁrst NCCT changes described in
acute ischemic stroke [7] .T h ep r e s e n c eo faH M C A Si s
associated with severe initial neurological deﬁcits and poor
outcomes following thrombolytic therapy with intravenous
recombinant tissue plasminogen activator (rtPA) [8–10].
The persistence of a HMCAS following thrombolysis is also
associated with a poor functional outcome [11].
More recently,the hyperdense internal carotid artery sign
(HICAS) has been suggested as a common marker of termi-
nal internal carotid artery thrombus [12]. The HICAS has
been described as a hyperdensity in the distal segment of
the internal carotid artery (ICA) seen on NCCT, which is
indicative of thrombus within the supraclinoid segment of
the distal ICA. In a previous study of 71 patients receiving
intravenous and/or intra-arterial rtPA, a HICAS was present
in nearly a quarter of patients and was associated with both a
severe initial neurological deﬁcit and a poor outcome [12].
We aimed to further investigate the prevalence of the
HICAS in a larger, unselected cohort of patients undergo-
ing intravenous thrombolysis. We also aimed to investigate2 Stroke Research and Treatment
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Figure 1: (a) NCCT demonstrating HICAS (arrow). (b) CT Carotid Angiogram demonstrating corresponding terminal carotid occlusion
(arrow). (c) NCCT demonstrating HMCAS (arrow).
the association of the HICAS with initial severity of neuro-
logical deﬁcit and its role as prognostic marker in patients
receiving intravenous rtPA.
2.Subjectsand Methods
Between December 2007 and May 2010, 123 consecutive
patients with acute ischemic stroke were treated with intra-
venous rtPA at Aintree Stroke Centre. Demographic infor-
mation, stroke risk factors, baseline neurological deﬁcit, and
functional outcome at discharge were documented prospec-
tively. For the present study, 120 patients were included. 3
patients were excluded from analysis as they were initially
imaged at other centres and as such their prethrombolysis
NCCTs were not available for review. All patients received
thrombolysis with intravenous rtPA 0.9milligrams/kg
administered in line with standard thrombolysis protocols.
2.1. Analysis of Radiological Data. Each patient had a pre-
treatment NCCT scan and a second scan at 24 hours follow-
ing thrombolysis.
30 patients were imaged with a single slice CT scanner,
with a section thickness of 4mm through the posterior fossa
and 8mm for the cerebral hemispheres.
The remaining 90 patients were imaged by 4- and 16-
slice scanners with asection thicknessof 2.5mm through the
posterior fossa and 5mm for the cerebral hemispheres.
All 120 NCCT scans were reviewed retrospectively and
independently by a radiologist (SB) and a stroke fellow (PF).
Both investigators were blinded to all clinical information
and inspected the prethrombolysis NCCTscans for the pres-
enceofaHICASand/oraHMCAS.TheHMCASwasdeﬁned
as “an MCA denser than its contralateral counterpart” [13].
The HICAS was deﬁned as “A hyperdensity of the supr-
aclinoid part of the ICA observed in the prepontine or pre-
mesencephalic cistern where the vessels form the Circle of
Willis.” A HICAS was deemed to be present if the distal ICA
was denserthan its contralateral counterpart [12]( Figure 1).
Both signs were rated as either present or absent. Dis-
agreements were settled by a third, more experienced inves-
tigator (RD), who was also blinded to all clinical data.
2.2. Clinical Assessment. Severity of neurological deﬁcits at
baseline and 24 hours after thrombolysis were assessed
prospectively by using the National Institutes of Health
Stroke Scale (NIHSS) conducted by clinicians certiﬁed in
NIHSS scoring. Patients with NIHSS ≥10 at 24 hours were
considered to have severe early postthrombolysis neurolog-
ical deﬁcits. Barthel scoring was undertaken at discharge
as is routine practice in our unit. Poor outcome following
thrombolysis was deﬁned as a discharge Barthel score <15 or
inpatient death. Haemorrhagic conversion following throm-
bolysis was deﬁned as any intracranial haemorrhage on
NCCT 24 hours after thrombolysis.
2.3. Statistical Analysis. Data was analysed in GraphPad
Prism 4.0 (GraphPad Software, San Diego, Calif, USA). The
D’Agostino-Pearson omnibus test was used to test contin-
uous data for normality. Paired/unpaired t-tests were used
to compare normally distributed continuous variables with
Mann-Whitney U tests used to compare nonparametrically
distributed continuous data. Fisher’s exact test was used to
analyse categoricalvariables. Interobserver agreementfor the
HICAS and the HMCAS was assessed using Cohen’s Kappa.
Statistical signiﬁcance was set at 0.05.
2.4.Ethical Review. Theprojectprotocolwasreviewed bythe
chair of the local Research Ethics Committee.
3.Results
120patientswereassessed. AHICASwaspresentin3patients
(2.5%) and absent in 117 (97.5%). Table 1 demonstrates
baseline characteristics and outcomes of patients with a
HICAS and without a HICAS.Stroke Research and Treatment 3
Table 1: Baseline characteristics and outcomes of patients with or
without HICAS present.
Patients with
HICAS
Patients without
HICAS
n = 3 n = 117 P
Age 72.0 (65.4–78.6) 69.7 (67.5–71.9) 0.742
Female 2 (66.6%) 51 (43.6%) 1.0
Baseline NIHSS 21.0 (16.7–25.3) 12.8 (11.7–13.9) 0.019
Time to rtPA
(minutes) 176 (37–315) 162 (151–173) 0.626
Atrial ﬁbrillation 1 (33.3%) 27 (23.1%) 0.553
Hyperlipidaemia 2 (66.6%) 42 (35.9%) 0.554
Angina 0 (0%) 20 (17.1%) 1.0
Peripheral vascular
disease 0 (0%) 6 (5.1%) 1.0
Hypertension 2 (66.6%) 72 (61.5%) 1.0
Myocardial
infarction 0 (0%) 11 (9.4%) 1.0
Diabetes mellitus 0 (0%) 14 (11.9%) 1.0
Current smoker 1 (33.3%) 24 (20.5%) 0.507
Haemorrhagic
conversion 0 (0%) 6 (5.1%) 1.0
24 hour NIHSS ≥10 2 (66.6%) 44 (37.1%) 0.559
inpatient death 0 (0%) 19 (16.2%) 1.0
Poor outcome 2 (66.6%) 45 (38.5%) 0.560
Values are mean (95% conﬁdence interval) or n (%) as appropriate.
Poor outcome deﬁned as discharge Barthel score <15 or inpatient death.
Inthe3patientsdisplayingaHICASthe meanmaximum
density of the aﬀected supraclinoid ICA measured in the
Hounsﬁeld units was signiﬁcantly higher than on the unaf-
fected side. Mean maximum density of the hyperdense ICA
56.3HU (95% CI 46.3 to 66.4), mean maximum density of
the ICA on the unaﬀected side 28.3HU (95% CI 26.9 to
29.7), P = 0.0067.
A HMCAS was present in 22 patients (18.3%). Patients
w i t haH M C A Ss h o w e dan o n s i g n i ﬁ c a n tt r e n dt o w a r d s
displaying a HICAS (9.1% versus 1%), odds ratio (OR)
9.7 (95% CI 0.834 to 12.3), P = 0.086. In the 2 patients
who displayed both HICAS and HMCAS, a continuous
hyperdensityrepresentingclotwasseenbetweentheterminal
ICA and MCA. Table 2 demonstrates baseline characteristics
and outcomes of patients with a HMCAS and without a
HMCAS.
InthepatientsdisplayingaHMCAS,themeanmaximum
density of the aﬀected MCA measured in the Hounsﬁeld
units was signiﬁcantly higher than on the unaﬀected side.
Mean maximum density of the hyperdense MCA 46.3HU
(95% CI 44.0 to 48.6), mean maximum density of the MCA
on the unaﬀected side 35.4 HU (95% CI 32.2 to 38.5), P<
0.0001.
3.1. Baseline Neurological Deﬁcit and Haemorrhagic Con-
version. Patients with a HICAS had a signiﬁcantly higher
baseline mean NIHSS score (Mean NIHSS 21.0 95% CI 16.7
Table 2: Baseline characteristics and outcomes of patients with or
without HMCAS present.
Patients with
HMCAS
Patients without
HMCAS
n = 22 n = 98 P
Age 69.9 (65.1–74.9) 69.7 (67.3–72.1) 0.935
Female 12 (54.5%) 41 (41.8%) 0.344
Baseline NIHSS 16.5 (14.3–18.7) 12.8 (11.1–13.4) 0.0025
Time to rtPA
(minutes) 157 (135–180) 165 (153–178) 0.577
HICAS present 2 (9.1%) 1 (1.0%) 0.086
Atrial ﬁbrillation 6 (27.3%) 22 (22.4%) 0.590
Hyperlipidaemia 9 (40.9%) 35 (35.7%) 0.635
Angina 5 (22.7%) 15 (15.3%) 0.526
Peripheral
vascular disease 1 (4.5%) 5 (5.1%) 1.0
Hypertension 13 (59.1%) 61 (62.2%) 0.812
Myocardial
infarction 1 (4.5%) 10 (10.2%) 0.687
Diabetes mellitus 3 (13.6%) 11 (11.2%) 0.720
Current smoker 6 (27.3%) 19 (19.4%) 0.397
Haemorrhagic
Conversion 3 (13.6%) 3 (3.1%) 0.074
24 hour NIHSS
≥10 20 (90.1%) 32 (32.7%) <0.0001
Inpatient death 4 (18.1%) 15 (15.3%) 0.750
Poor outcome 14 (63.6%) 33 (33.7%) 0.015
Values are mean (95% conﬁdence interval) or n (%) as appropriate.
Poor outcome deﬁned as discharge Barthel score <15 or inpatient death.
to 25.3) compared to those without this sign (Mean NIHSS
12.8 95% CI 11.7 to 13.9, P = 0.019).
The presence of a HMCAS was also associated with sig-
niﬁcantly more severe prethrombolysis neurological deﬁcits
(Mean NIHSS 16.5 95% CI 14.3 to 18.7) when compared to
patients without a HMCAS (Mean NIHSS 12.3 95% CI 11.1
to 13.4, P = 0.0025).
Haemorrhagic conversion occurred in 5% of patients,
a ni n c i d e n c ec o m p a r a b l et ot h a ts e e ni nt h eS I T S - M O S T
monitoring study [14]. No signiﬁcant associations were
observed between the presence of a HICAS (OR 2.45 95%
CI 0.11 to 52.7, P = 1.0) or a HMCAS (OR 5.0 95% CI 0.94
to 26.7, P = 0.074) and intracranial haemorrhage following
thrombolysis.
3.2. Short-Term and Long-Term Outcomes Following Throm-
bolysis. At 24 hours following thrombolysis, severe neuro-
logical deﬁcits (NIHSS score ≥10 points) were observed in
2 of 3 patients (66.6%) with a HICAS compared to 44 of 117
patients (37.1%) without a HICAS, OR 3.20 95% CI 0.28 to
36.7, P = 0.559.
The presence of a HICAS on prethrombolysis NCCT was
not signiﬁcantly associated with a poor outcomeat discharge
(Barthel <15 or impatient death). Of the 3 patients with
a HICAS, 2 (66%) had a poor outcome, compared with4 Stroke Research and Treatment
45 (38.5%)ofthe 117 patientswithout HICAS,OR 3.20 95%
CI 0.28 to 36.34, P = 0.560.
The presence of a HICAS was not signiﬁcantly associated
with inpatient death (P = 1.0).
The presence of a HMCAS on initial prethrombolysis
NCCT was signiﬁcantly associated with both a severe neuro-
logical deﬁcit at 24 hours following thrombolysis and a poor
outcome at discharge.
A 24-hour NIHSS score of ≥10 was seen in 20 of 22
patients (90.1%) of patients with a HMCAS and 32 of 98
(32.7%) of those without a HMCAS, OR 20.6 95% CI 4.54
to 93.7, P<0.0001.
A poor outcome at discharge was observed in 14 of 22
(63.6%) patients with a HMCAS compared with 33 of 98
(33.7%) without a HMCAS, OR 3.45 95% CI 1.31 to 9.04,
P = 0.015.
The presence of a HMCAS was not signiﬁcantly associ-
ated with inpatient death (P = 0.750).
3.3. Interobserver Agreement for the Hyperdense ICA and Hy-
perdense MCA Signs. Interobserver agreement was excellent
for the HMCAS-Cohen’s Kappa 0.973 (95% CI 0.919 to
0.999) and fair for the HICAS-Cohen’sKappa 0.275 (95% CI
0.0 to 0.704).
4.Discussion
In the ﬁrst hours following acute ischaemic stroke, NCCT
frequently demonstrates early parenchymal changes which
m a yb ep r e c e d e db yh y p e r d e n s ea r t e r ys i g n ss u g g e s t i v eo f
intraluminal thrombus [15]. These early ischemic changes
on NCCT are of prognostic signiﬁcance in predicting func-
tional outcome before thrombolysis is administered [1, 2].
Ourstudyaimedtofurtherinvestigatetheprevalenceand
prognostic signiﬁcance of the HICAS. Two previous studies
havedescribeddistalICAthrombusresultinginahyperdense
appearanceoftheterminalICAonNCCT[12,16].Ourstudy
contains the largest series of patients to date and is the ﬁrst
study to include an unselected series of patients receiving
intravenous thrombolysis with rtPA.
A HICAS was present in 2.5% of the patients included
in our study, this did not diﬀer signiﬁcantly from the 5.8%
prevalence reported in the ﬁrst paper to describe the HICAS
[16] but does represent a signiﬁcantly lower prevalence
than the 24% reported in patients receiving thrombolysis by
Ozdemir et al. (Fisher’s exact test; P<0.0001) [12].
The lower prevalence of the HICAS observed in our
series of patients undergoing thrombolysis may in part be
explained by the NCCT imaging protocols employed. A
quarter of the NCCT scans reviewed in our study used
a thicker 8mm slice rather than the 5mm slices used by
Ozdemir et al. [12]. A previous study has demonstrated that
areductioninslicethicknessisassociated withincreased sen-
sitivity in identifying hyperdense intracerebral arteries [16],
as such the thicker slices used in some of the scans included
in our study may have resulted in false negatives. However,
even if these thicker 8mm slice NCCT are excluded from
analysis, the proportion of patients with a HICAS remains
signiﬁcantly lower than that described by Ozdemir et al. [12]
and comparabletothatobservedintheﬁrst study todescribe
the HICAS [16].
Our data suggests the prevalence of the HICAS seen on
standard prethrombolysis NCCT slices may be lower than
that previously reported.
Occlusion of the intracranial ICA is a potentially catas-
trophic event. When the distal intracranial ICA is acutely
occluded patients are frequently refractory to intravenous
thrombolysis and the outcome is often poor [17–19]. The
signiﬁcantly higher prethrombolysis NIHSS scores seen in
patients with a HICAS in our study reﬂect the severe neuro-
logical deﬁcits seen with terminal ICA thrombotic occlusion
and are comparable to the ﬁndings of a previous study [12].
Unlike the previous study undertaken by Ozdemir et al.,
we failed to demonstrate a signiﬁcant association between
the presence of a HICAS and severe early post thrombol-
ysis neurological deﬁcits or long term outcomes following
thrombolysis [12]. Patients with a HICAS did display non-
signiﬁcant trends towards poor outcomes. Due to the low
prevalence of the HICAS in our sample, our study lacked
suﬃcient power to accurately determine the prognostic
signiﬁcance of the HICAS and the failure to demonstrate an
association between the HICAS and poor outcomes in the
present study may be attributable to a type II error. While 2
of the 3 patients with a HICAS failed to make any clinically
signiﬁcant improvement when treated with intravenous rt-
PA, 1 of the 3 patients with a HICAS in our study showed
an extremely good response to intravenous rt-PA, with an
admission NIHSS of 22 decreasing to 8 at 24 hours post
thrombolysis. This patients repeat CT scan at 24 hours
post thrombolysis demonstrated resolution of the HICAS,
suggestive of clot lysis and recanalisation. This patients un-
usually good response to peripheral rt-PA [17–19]m a yh a v e
contributed a suspected type II error.
Patients with a HMCAS displayed signiﬁcantly more se-
vere baseline neurological deﬁcits than those patients with-
out this sign. The HMCAS was also associated with poor
neurological and functional outcomes at 24 hours and at
discharge. The signiﬁcant associations observed between the
HMCAS and both severe baseline neurological deﬁcits and
poor outcomes are in keeping with the ﬁndings of several
previous studies [8–10].
Interobserver agreement was excellent for the HMCAS.
Interobserver agreement for the HICAS was only fair; how-
ever, this result should be viewed with caution given the low
prevalenceoftheHICASinourstudypopulation,asreﬂected
by the wide conﬁdence intervals seen for Cohen’s kappa.
Our study has several limitations. While all clinical data
including risk factors, demographics, and outcome follow-
ing thrombolytic therapy were collected prospectively, pre-
thrombolysis NCCTs were studied retrospectively.
None of the patients included in our study underwent
CT angiography prior to intravenous thrombolysis. As
such, we are unable to validate the sensitivity and speciﬁcity
of the HICAS in detecting terminal ICA thrombus against
the gold standard of CT angiogram. Validation of pre-
sumed thrombotic occlusion against angiographic data may
be of particular importance when investigating hyperdenseStroke Research and Treatment 5
artery signs as vessel calciﬁcation resulting in a false-positive
HMCASis well recognised [10, 15, 20]. We do, howevernote
thatbothstudieswhich havepreviouslydescribedtheHICAS
found no false positives when the HICAS was validated as
a marker of terminal ICA thrombus using CT angiography
[12, 16]. This suggests that the HICAS is less prone to false
positives attributable to calciﬁed vessels than the HMCAS.
A quarter of the patients included in our study were im-
aged using 8mm through the cerebral hemispheres, with the
remainder imaged using 5mm sections. A previous study
in nonthrombolysed acute stroke patients has shown that
reductionofsection thicknessfrom5mm to1mm improved
the sensitivity of detecting intraluminal ICA thrombus from
33% to 100% without reducing speciﬁcity. This may account
for the low prevalence of the HICAS in our study and
the low sensitivity reported in previous studies using 5mm
slices [12, 16]. Future studies using prethrombolysis thin
slice NCCT through the course of the ICA as it traverses
the prepontine, and premesencephalic cisterns should allow
improved sensitivity in detecting distal ICA thrombus and
may improve the predictive power of the HICAS as a prog-
nostic marker.
In summary, this study suggests the prevalence of the
HICAS on standard prethrombolysis NCCT may be lower
than that previously reported. The presence of a HICAS was
associated with signiﬁcantly more severe initial neurological
deﬁcits in keeping with acute terminal ICA occlusion. Larger
studies, ideally using thin slice CT through the course of the
terminal ICA, are required to further investigate the preva-
lence and prognostic signiﬁcance of the HICAS in stroke
patients receiving thrombolytic therapy.
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